NEFH (Neurofilament Heavy Chain) <table class="infobox infobox-gene"> <tr> <th class="infobox-header" colspan="2">NEFH Gene</th> </tr> <tr> <td class="label">Condition</td> <td>NEFH/NfL Significance</td> </tr> <tr> <td class="label">Multiple Sclerosis</td> <td>Axonal injury marker, disease activity</td> </tr> <tr> <td class="label">Charcot-Marie-Tooth disease</td> <td>Diagnostic, severity correlation</td> </tr> <tr> <td class="label">Creutzfeldt-Jakob disease</td> <td>Rapidly rising NfL</td> </tr> <tr> <td class="label">Frontotemporal dementia</td> <td>Differentiation from AD</td> </tr> <tr> <td class="label">Vascular dementia</td> <td>Vascular burden indicator</td> </tr> <tr> <td class="label">Condition</td> <td>NfL Elevation</td> </tr> <tr> <td class="label">ALS</td> <td>++ (very high)</td> </tr> <tr> <td class="label">CBD/PSP</td> <td>++ (high)</td> </tr> <tr> <td class="label">PD</td> <td>+ (mild)</td> </tr> <tr> <td class="label">AD</td> <td>+ (mild-moderate)</td> </tr> <tr> <td class="label">MS</td> <td>Variable</td> </tr> <tr> <td class="label">Protein</td> <td>Interaction Type</td> </tr> <tr> <td class="label">NEFL</td> <td>Co-assembly</td> </tr> <tr> <td class="label">NEFM</td> <td>Co-assembly</td> </tr> <tr> <td class="label">Tau (MAPT)</td> <td>Co-localization</td> </tr> <tr> <td class="label">Kinesin-1</td> <td>Transport</td> </tr> <tr> <td class
...
NEFH (Neurofilament Heavy Chain) <table class="infobox infobox-gene"> <tr> <th class="infobox-header" colspan="2">NEFH Gene</th> </tr> <tr> <td class="label">Condition</td> <td>NEFH/NfL Significance</td> </tr> <tr> <td class="label">Multiple Sclerosis</td> <td>Axonal injury marker, disease activity</td> </tr> <tr> <td class="label">Charcot-Marie-Tooth disease</td> <td>Diagnostic, severity correlation</td> </tr> <tr> <td class="label">Creutzfeldt-Jakob disease</td> <td>Rapidly rising NfL</td> </tr> <tr> <td class="label">Frontotemporal dementia</td> <td>Differentiation from AD</td> </tr> <tr> <td class="label">Vascular dementia</td> <td>Vascular burden indicator</td> </tr> <tr> <td class="label">Condition</td> <td>NfL Elevation</td> </tr> <tr> <td class="label">ALS</td> <td>++ (very high)</td> </tr> <tr> <td class="label">CBD/PSP</td> <td>++ (high)</td> </tr> <tr> <td class="label">PD</td> <td>+ (mild)</td> </tr> <tr> <td class="label">AD</td> <td>+ (mild-moderate)</td> </tr> <tr> <td class="label">MS</td> <td>Variable</td> </tr> <tr> <td class="label">Protein</td> <td>Interaction Type</td> </tr> <tr> <td class="label">NEFL</td> <td>Co-assembly</td> </tr> <tr> <td class="label">NEFM</td> <td>Co-assembly</td> </tr> <tr> <td class="label">Tau (MAPT)</td> <td>Co-localization</td> </tr> <tr> <td class="label">Kinesin-1</td> <td>Transport</td> </tr> <tr> <td class="label">Calmodulin</td> <td>Calcium binding</td> </tr> <tr> <td class="label">Associated Diseases</td> <td><a href="/wiki/ms" style="color:#ef9a9a">Ms</a></td> </tr> <tr> <td class="label">KG Connections</td> <td><a href="/atlas" style="color:#4fc3f7">15 edges</a></td> </tr> </table>
Overview
Mermaid diagram (expand to render)
NEFH (Neurofilament Heavy Chain) is a neuronal intermediate filament protein encoded by the NEFH gene on chromosome 22q12.2[@julien1985]. As the largest neurofilament subunit (molecular weight ~200 kDa), NEFH plays a critical role in maintaining axonal caliber and conducting velocity in large myelinated neurons. Neurofilament light chain (NfL) and phosphorylated NEFH are widely used as biomarkers for axonal injury in Alzheimer's disease, Parkinson's disease, ALS, and other neurodegenerative conditions["@zetterberg2016"].
Gene Structure and Expression The NEFH gene spans approximately 3.5 kb and contains 4 exons. It encodes a protein of 1,816 amino acids, the largest of the neurofilament subunits.
Domain structure:
N-terminal head domain : Regulatory (phosphorylation, interactions)
Alpha-helical rod domain : Coiled-coil formation (600 residues)
C-terminal tail domain : KSP repeats (lysine-serine-proline), heavily phosphorylated
Expression pattern:
Primary : Large myelinated neurons (motor neurons, sensory neurons)
Brain regions : Spinal cord gray matter, dorsal root ganglia, cerebral cortex layer 5 pyramidal cells
Peripheral : Peripheral nerves (sciatic, vagus)
Molecular Function
NEFH assembles with other neurofilament subunits to form the neuronal cytoskeleton:
Heteropolymer formation : NEFH co-assembles with NEFL (light) and NEFM (medium) subunits
Phosphorylation-dependent assembly : Tail domain phosphorylation regulates filament spacing
Cross-bridging : NEFH sidearms connect adjacent filaments, establishing axonal caliber
Axonal Transport NEFH is transported along axons via:
Slow transport : Part of the slow component a (SCa) system (~0.5 mm/day)
Kinesin/dynactin mediated : Bidirectional movement
Post-translational modifications : Phosphorylation state affects transport rate
Electrophysiological Function The neurofilament network determines:
Axonal diameter : Larger diameter = faster conduction velocity
Saltatory conduction efficiency : Optimal for myelinated fibers
Node of Ranvier organization : Neurofilament organization at paranodes
Role in Neurodegeneration
Alzheimer's Disease
Axonal degeneration marker : NEFL and NfL in CSF correlate with disease severity[@blennow2015]
Tau pathology relationship : Neurofilament abnormalities occur secondary to tau pathology
Predictive biomarker : Elevated NfL predicts cognitive decline in preclinical AD
Longitudinal tracking : NfL levels increase with disease progression
Parkinson's Disease
Axonal loss indicator : NfL in CSF reflects dopaminergic neuron degeneration
Disease progression : Higher levels correlate with more severe motor symptoms
DLB overlap : Elevated NfL in dementia with Lewy bodies
Differentiation : Can help differentiate PD from atypical parkinsonism
Amyotrophic Lateral Sclerosis (ALS) NEFH is particularly important in ALS:
Cytoplasmic inclusions : Phosphorylated NEFH accumulates in motor neuron spheroids
Biomarker : NfL in CSF/blood is highly sensitive for axonal loss[@benatar2018]
Prognostic value : Higher NfL = shorter survival
Trial endpoint : NfL used as outcome measure in clinical trials
Mutations : NEFH mutations cause rare forms of ALS (autosomal recessive)
Other Neurodegenerative Conditions
Clinical Significance
Biomarker Applications CSF (Cerebrospinal Fluid):
NfL: Gold standard for axonal injury
pNfH: Phosphorylated NEFH, more specific
NFL/NEFH ratio: Disease differentiation
Blood (Plasma/Serum):
NfL: Less invasive than lumbar puncture
Age-adjusted cutoffs: Critical for interpretation
Simoa technology: Ultra-sensitive detection
Diagnostic Utility
Therapeutic Implications
Neuroprotective strategies : NfL as endpoint to assess efficacy
Axonal regeneration : Targeting neurofilament phosphorylation to enhance regrowth
Gene therapy : NEFH overexpression to restore axonal caliber
Key Interactions
See Also
[Alzheimer's Disease](/diseases/alzheimers-disease)
[Parkinson's Disease](/diseases/parkinsons-disease)
External Links
[PubMed](https://pubmed.ncbi.nlm.nih.gov/)
[KEGG Pathways](https://www.genome.jp/kegg/pathway.html)
References
[Julien, J.P., et al, (1985) (1985)](https://pubmed.ncbi.nlm.nih.gov/3875555/)
[Zetterberg, H., et al, (2016) (2016)](https://pubmed.ncbi.nlm.nih.gov/27252480/)
[Blennow, K., et al, (2015) (2015)](https://pubmed.ncbi.nlm.nih.gov/26260681/)
[Benatar, M., et al, (2018) (2018)](https://pubmed.ncbi.nlm.nih.gov/30072406/)
Pathway Diagram The following diagram shows the key molecular relationships involving NEFH Gene discovered through SciDEX knowledge graph analysis:
Mermaid diagram (expand to render)
Show full description